Testosterone Cypionate: EMA vs FDA Regulatory Approach

FDA Approval History and Label Evolution

Testosterone cypionate received FDA approval in 1979 under the brand name Depo-Testosterone, manufactured by Upjohn (now Pfizer). The original indication was limited to replacement therapy in males with conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism 1.

The label has changed substantially since 1979. In 2015, the FDA mandated a class-wide label revision for all approved testosterone products, adding warnings about possible increased risk of heart attack and stroke 2. That same revision narrowed the indicated population, clarifying that testosterone products are approved only for men with low testosterone caused by certain medical conditions (structural or genetic defects of the hypothalamic-pituitary-gonadal axis), not for age-related decline alone. The FDA explicitly stated that the benefits and safety of testosterone for age-related low testosterone "have not been established" 3.

A further revision in 2023 strengthened cardiovascular language after data from the TRAVERSE trial (N=5,246) showed a non-inferior but not zero cardiovascular signal with testosterone treatment in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease 4. The current label includes polycythemia, venous thromboembolism, and major adverse cardiovascular events (MACE) among its warnings and precautions.

Why the EMA Does Not Approve Testosterone Cypionate

The EMA has never granted a centralized marketing authorization for testosterone cypionate. This is not a safety ban. It reflects market preference and pharmacokinetic considerations that led European manufacturers to develop testosterone undecanoate (Nebido, Bayer) as the dominant long-acting injectable ester 5.

Testosterone undecanoate allows dosing every 10 to 14 weeks after an initial loading phase, compared with every 2 to 4 weeks for cypionate. The EMA's Committee for Medicinal Products for Human Use (CHMP) evaluated testosterone undecanoate through the centralized procedure in 2004 and granted authorization based on pharmacokinetic studies demonstrating stable serum testosterone levels with fewer injections 5. Individual EU member states may authorize testosterone cypionate through national procedures, but none currently hold active marketing authorizations for this specific ester.

The practical result: a U.S. patient prescribed testosterone cypionate 200 mg IM every two weeks has no direct European equivalent by ester. Their European counterpart typically receives testosterone undecanoate 1 to 000 mg IM every 10 to 14 weeks, or a shorter-acting ester such as testosterone enanthate (Testoviron, available in several EU markets through national authorization).

Labeling Differences: Indications and Dosing

The FDA label for testosterone cypionate lists two categories of approved use: primary hypogonadism (testicular failure due to conditions such as Klinefelter syndrome, bilateral torsion, or orchitis) and hypogonadotropic hypogonadism (pituitary or hypothalamic origin, including Kallmann syndrome, pituitary tumors, or idiopathic GnRH deficiency) 1. The labeled dose range is 50 to 400 mg intramuscularly every 2 to 4 weeks. Dose adjustments are guided by serum testosterone trough levels, with a target range of 300 to 1 to 000 ng/dL per the Endocrine Society's 2018 clinical practice guideline 6.

For testosterone undecanoate under EMA authorization, the Summary of Product Characteristics (SmPC) specifies an initial injection of 1 to 000 mg, a second injection at 6 weeks, then maintenance injections every 10 to 14 weeks. The indication language in the SmPC is broader in one respect: it references "testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests" without subdividing into primary and secondary categories as explicitly as the FDA label does.

A notable difference involves female patients. The FDA label for testosterone cypionate contains a contraindication in women who are or may become pregnant (Pregnancy Category X). The EMA's testosterone undecanoate SmPC similarly contraindicates use in women but through a different regulatory mechanism, as the EMA does not use the letter-grade pregnancy category system.

Post-Market Surveillance: FDA Sentinel vs EMA EudraVigilance

The two agencies monitor testosterone safety through fundamentally different surveillance architectures. The FDA relies on its Sentinel System, a distributed data network covering over 100 million patients through electronic health records and insurance claims data 7. Sentinel allows the FDA to run active queries against real-world data. The 2015 cardiovascular label change was partially informed by Sentinel analyses, along with published observational studies such as the Finkle et al. (2014) cohort study that found a twofold increase in myocardial infarction rates in the 90 days following a testosterone prescription among men aged 65 and older 8.

The EMA uses EudraVigilance, a centralized database for suspected adverse drug reactions reported from across the European Economic Area. Marketing authorization holders are required to submit Periodic Safety Update Reports (PSURs) at defined intervals. In 2014, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a review of all testosterone-containing medicines following the same cardiovascular signal that prompted the FDA's action 9. PRAC concluded that the evidence did not support a consistent increased cardiovascular risk and did not mandate a boxed warning equivalent, instead recommending continued monitoring and updated product information noting the cardiovascular uncertainty.

This divergence is significant. The FDA added explicit cardiovascular warnings. PRAC determined the data were inconclusive. Both agencies reviewed overlapping evidence. They reached different regulatory conclusions.

The TRAVERSE Trial and Its Regulatory Impact

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) was a randomized, double-blind, placebo-controlled trial of 5,246 men aged 45 to 80 with hypogonadism and established cardiovascular disease or elevated cardiovascular risk 4. Participants received transdermal testosterone gel (not injectable cypionate), with a mean follow-up of 33 months.

The primary endpoint (first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78 to 1.17), meeting the prespecified noninferiority margin. TRAVERSE did not demonstrate increased MACE risk. It also did not prove cardiovascular safety, as the upper bound of the confidence interval (1.17) did not exclude a clinically meaningful increase.

The FDA used TRAVERSE data to update labeling in 2023, noting the noninferiority finding but retaining cardiovascular warnings. The EMA has not issued a corresponding label update for testosterone-containing products based on TRAVERSE, partly because the trial used a transdermal formulation and partly because EMA's existing position already characterized the cardiovascular evidence as inconclusive 9.

The TTrials: Efficacy Evidence That Shaped Both Agencies

The Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism 10. Seven coordinated sub-trials evaluated the effects of testosterone gel versus placebo on sexual function, physical function, vitality, cognition, anemia, bone density, and cardiovascular imaging (coronary artery plaque).

Testosterone treatment increased sexual activity scores by 0.58 points on the Psychosexual Daily Questionnaire (P<0.001) and modestly improved walking distance. The vitality sub-trial showed small but statistically significant improvements in the FACIT-Fatigue scale. The bone mineral density sub-trial demonstrated increases in volumetric bone mineral density of the lumbar spine by 7.5% compared with placebo over 12 months.

The cardiovascular sub-trial, however, found increased coronary artery noncalcified plaque volume in the testosterone group, raising concern about subclinical atherosclerosis progression 11. This finding contributed to the FDA's decision to maintain cardiovascular warnings despite the later TRAVERSE noninferiority result.

The Endocrine Society's 2018 guideline referenced the TTrials extensively, recommending that clinicians discuss the uncertain cardiovascular risk profile before initiating testosterone therapy in older men 6. Dr. Peter Snyder, the TTrials principal investigator, stated: "The trials showed clear benefits for sexual function and bone density, but the cardiovascular imaging findings mean we cannot yet assure men that testosterone treatment is free of cardiovascular risk."

Controlled Substance Classification

The U.S. Controlled Substances Act classified all anabolic steroids, including testosterone cypionate, as Schedule III substances in 1990 under the Anabolic Steroids Control Act 12. This places prescribing and dispensing requirements on testosterone cypionate that do not apply to non-controlled medications: prescriptions must include DEA numbers, refill limits apply (five refills within six months of the original prescription date), and state-level prescription drug monitoring program (PDMP) reporting is required in most states.

The EU does not have a unified controlled substance schedule. Each member state classifies anabolic steroids independently. Germany, for example, classifies testosterone as a prescription-only medication under the Arzneimittelgesetz (AMG) but does not place it in the Betäubungsmittelgesetz (narcotics act) schedule. The United Kingdom (post-Brexit, outside EMA jurisdiction) classifies anabolic steroids as Class C controlled substances under the Misuse of Drugs Act 1971, making possession without a prescription an offense but allowing personal importation.

These classification differences affect clinical practice directly. A U.S. prescriber faces PDMP audits and DEA oversight. A German prescriber writes a standard prescription without narcotics-level documentation.

Polycythemia Monitoring: Where Both Agencies Agree

Despite their differences, both the FDA and EMA product information documents flag polycythemia (hematocrit above 54%) as a dose-limiting adverse effect requiring active monitoring. The FDA label recommends checking hematocrit at baseline, at 3 to 6 months, then annually 1. The Endocrine Society guideline specifies hematocrit monitoring at 3 months, 6 months, and then every 6 to 12 months, with dose reduction or temporary discontinuation if hematocrit exceeds 54% 6.

Data from the TTrials showed that testosterone-treated men experienced a mean hematocrit increase of 2.5 percentage points from baseline, with 4.9% of testosterone-treated men exceeding a hematocrit of 54% compared to 0.8% in the placebo group 10. In TRAVERSE, 21.6% of testosterone-treated men had hematocrit values exceeding 54% at any time during follow-up versus 2.4% in the placebo group, leading to the protocol-specified dose adjustment in those participants 4.

Dr. Shalender Bhasin, principal investigator of TRAVERSE, noted: "The high rate of erythrocytosis in TRAVERSE reinforces that hematocrit monitoring is not optional. Any prescriber initiating testosterone, regardless of formulation, should have a monitoring protocol in place before the first dose."

What This Means for Prescribers and Patients

A clinician in the United States prescribing testosterone cypionate operates under a specific regulatory framework: Schedule III controls, a label that limits the indication to confirmed hypogonadism with an identified etiology, cardiovascular and polycythemia warnings, and Sentinel-driven post-market monitoring. A clinician in Europe prescribing injectable testosterone uses a different ester (undecanoate), faces no equivalent cardiovascular boxed warning, and complies with national rather than centralized controlled-substance rules.

Neither framework is objectively superior. The FDA's approach is more restrictive on labeling and more aggressive on cardiovascular warnings. The EMA's approach offers a pharmacokinetically longer-acting ester with less frequent dosing, fewer injection-site reactions, and arguably more stable serum levels.

Patients transferring care between the U.S. and Europe should expect a change in ester, dosing interval, and potentially the monitoring cadence. The target serum testosterone range (300 to 1 to 000 ng/dL, or approximately 10.4 to 34.7 nmol/L) is clinically equivalent across both systems, but the route to achieving that range differs based on which regulatory body approved the product their prescriber uses.

Hematocrit should be checked within 3 months of starting any testosterone formulation, repeated at 6 months, and monitored at least annually thereafter, per the Endocrine Society's 2018 guideline 6.